Terms: = Bone cancer AND CEBPA, CEBP, 1050, C/EBP-alpha, P49715 AND Clinical Outcome
4 results:
1. Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.
Strickland SA; Shaver AC; Byrne M; Daber RD; Ferrell PB; Head DR; Mohan SR; Mosse CA; Moyo TK; Stricker TP; Vnencak-Jones C; Savona MR; Seegmiller AC
Leuk Res; 2018 Feb; 65():67-73. PubMed ID: 29310020
[TBL] [Abstract] [Full Text] [Related]
2. Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia.
Cheng CL; Hou HA; Lee MC; Liu CY; Jhuang JY; Lai YJ; Lin CW; Chen HY; Liu FT; Chou WC; Chen CY; Tang JL; Yao M; Huang SY; Ko BS; Wu SJ; Tsay W; Tien HF
Blood; 2013 Apr; 121(16):3172-80. PubMed ID: 23449638
[TBL] [Abstract] [Full Text] [Related]
3. YY1 overexpression is associated with poor prognosis and metastasis-free survival in patients suffering osteosarcoma.
de Nigris F; Zanella L; Cacciatore F; De Chiara A; Fazioli F; Chiappetta G; Apice G; Infante T; Monaco M; Rossiello R; De Rosa G; Alberghini M; Napoli C
BMC Cancer; 2011 Nov; 11():472. PubMed ID: 22047406
[TBL] [Abstract] [Full Text] [Related]
4. Heterogeneity within AML with cebpa mutations; only cebpa double mutations, but not single cebpa mutations are associated with favourable prognosis.
Pabst T; Eyholzer M; Fos J; Mueller BU
Br J Cancer; 2009 Apr; 100(8):1343-6. PubMed ID: 19277035
[TBL] [Abstract] [Full Text] [Related]
